KROS - Keros Therapeutics: Very Expensive For A Company Still In Early Stages Of Development
- Keros Therapeutics, a clinical stage biopharmaceutical company with no close-to-market product in its three-candidate pipeline, has seen a stupendous rally in its stock price.
- KROS is currently focused on less frequently occurring diseases, with its lead candidate KER-050 targeting the treatment of cytopenias in patients with Myelodysplastic Syndromes.
- Product approvals and sales of KROS are still ~2-3 years away, and the stock price seems to have already priced in those developments.
For further details see:
Keros Therapeutics: Very Expensive For A Company Still In Early Stages Of Development